To assess the effects of taxanes as part of a combined or single-agent therapy versus other agents or best supportive care as first- or second-line treatment for advanced non-small cell lung cancer (NSCLC).

A secondary objective is to assess different modes or schemes of administration of taxanes in patients with this disease.